Sionna Therapeutics (NASDAQ:SION) Director Sells $3,041,405.16 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Bruce Booth sold 88,878 shares of Sionna Therapeutics stock in a transaction on Tuesday, October 21st. The shares were sold at an average price of $34.22, for a total value of $3,041,405.16. Following the completion of the sale, the director directly owned 686,567 shares of the company’s stock, valued at $23,494,322.74. The trade was a 11.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Bruce Booth also recently made the following trade(s):

• On Thursday, October 16th, Bruce Booth sold 169,260 shares of Sionna Therapeutics stock. The stock was sold at an average price of $32.35, for a total value of $5,475,561.00.
• On Monday, October 20th, Bruce Booth sold 55,985 shares of Sionna Therapeutics stock. The stock was sold at an average price of $32.09, for a total value of $1,796,558.65.
• On Friday, October 17th, Bruce Booth sold 61,124 shares of Sionna Therapeutics stock. The stock was sold at an average price of $32.37, for a total value of $1,978,583.88.
• On Wednesday, October 15th, Bruce Booth sold 115,856 shares of Sionna Therapeutics stock. The stock was sold at an average price of $30.61, for a total value of $3,546,352.16.
• On Tuesday, October 14th, Bruce Booth sold 606 shares of Sionna Therapeutics stock. The stock was sold at an average price of $29.95, for a total value of $18,149.70.
• On Monday, October 13th, Bruce Booth sold 58,232 shares of Sionna Therapeutics stock. The stock was sold at an average price of $30.38, for a total value of $1,769,088.16.
• On Friday, October 10th, Bruce Booth sold 20,238 shares of Sionna Therapeutics stock. The stock was sold at an average price of $29.98, for a total value of $606,735.24.
• On Monday, October 6th, Bruce Booth sold 11,800 shares of Sionna Therapeutics stock. The stock was sold at an average price of $29.95, for a total value of $353,410.00.
• On Friday, October 3rd, Bruce Booth sold 37,746 shares of Sionna Therapeutics stock. The stock was sold at an average price of $30.00, for a total value of $1,132,380.00.
• On Wednesday, October 1st, Bruce Booth sold 200 shares of Sionna Therapeutics stock. The stock was sold at an average price of $29.95, for a total value of $5,990.00.

Sionna Therapeutics Price Performance

SION opened at $39.60 on Friday. Sionna Therapeutics, Inc. has a 12 month low of $7.26 and a 12 month high of $43.19. The business has a fifty day moving average price of $26.93 and a 200 day moving average price of $19.27.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.27.

Wall Street Analyst Weigh In

A number of analysts have issued reports on SION shares. Royal Bank Of Canada started coverage on Sionna Therapeutics in a report on Wednesday, September 3rd. They set a “sector perform” rating and a $22.00 price target for the company. Wall Street Zen raised Sionna Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. Raymond James Financial started coverage on Sionna Therapeutics in a report on Tuesday, September 2nd. They set a “strong-buy” rating and a $45.00 price target for the company. Jones Trading started coverage on Sionna Therapeutics in a report on Monday, September 8th. They set a “buy” rating and a $46.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sionna Therapeutics in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Sionna Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $38.00.

Institutional Trading of Sionna Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. RA Capital Management L.P. purchased a new stake in shares of Sionna Therapeutics in the 1st quarter valued at about $109,258,000. TPG GP A LLC purchased a new stake in shares of Sionna Therapeutics in the 1st quarter valued at about $69,925,000. Atlas Venture Life Science Advisors LLC purchased a new stake in shares of Sionna Therapeutics in the 1st quarter valued at about $38,639,000. Viking Global Investors LP lifted its holdings in shares of Sionna Therapeutics by 8.2% in the 2nd quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock valued at $55,436,000 after purchasing an additional 242,427 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Sionna Therapeutics by 2.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 2,221,188 shares of the company’s stock valued at $38,538,000 after acquiring an additional 51,589 shares during the last quarter.

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.